Republic of Turkey Purchases 60 Million Comirnaty Vaccine Doses

BioNTech Europe GmbH confirmed on May 20, 2021, it has agreed with the Republic of Turkey’s Ministry of Health to supply 60 million additional doses of the companies’ mRNA COVID-19 vaccine, with an option for an additional 30 million doses.

This second supply agreement brings the total number of Cominraty vaccine doses to Turkey to up to 120 million, all of which will be delivered in 2021.

“We are hopeful that this agreement will further boost Turkey’s COVID-19 vaccination drive. Pfizer is committed to contributing to public health in Turkey and very proud to have a global partner such as BioNTech in the global fight against the pandemic,” commented M. Cem Açık, Pfizer Country Manager Turkey, in a press statement.

The Comirnaty vaccine, based on BioNTech’s proprietary mRNA technology, was developed by BioNTech and Pfizer.

Do not administer the Pfizer-BioNTech COVID-19 vaccine to individuals with a known history of a severe allergic reaction to any component of the Pfizer-BioNTech COVID-19 vaccine.

Germany-based BioNTech SE is the Marketing Authorization Holder in the European Union and the holder of emergency use authorizations or equivalent in the United States (jointly with Pfizer), United Kingdom, Canada, and other countries in advance of a planned application for full marketing authorizations in these countries.